Sodium-Glucose Transporter 2 Inhibitors

DBCAT004076Pharmacologic class

Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney, and are used in the treatment of TYPE 2 DIABETES MELLITUS. A DrugBank category of 10 drugs. 5 of them are approved.

Drugs: Bexagliflozin
Dapagliflozin
Empagliflozin
Ertugliflozin
Ipragliflozin
Licogliflozin
Remogliflozin etabonate
Sergliflozin etabonate
Sotagliflozin
Tofogliflozin

What you can answer from here — as of September 06, 2018

10DrugsEach linked to its full drug card

Listed above

3Drug targetsEvery drug–target pair in the class, with bond type

943Marketed productsAcross the regions we cover, with dosage forms and routes

1Route of administrationHow the drugs in this class are given

Which targets do Sodium-Glucose Transporter 2 Inhibitors share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account